Literature DB >> 19828235

Widdrol induces cell cycle arrest, associated with MCM down-regulation, in human colon adenocarcinoma cells.

Hyun Ju Kwon1, Yun Kyung Hong, Cheol Park, Yung Hyun Choi, Hee Jung Yun, Eun Woo Lee, Byung Woo Kim.   

Abstract

Widdrol, an odorous compound extracted from Juniperus chinensis, has been shown to inhibit the in vitro growth of in human cancer cells. This study was conducted on cultured human colon adenocarcinoma HT29 cells to elucidate the possible mechanisms by which widdrol exerts its anti-proliferative activity, which until now has remained poorly understood. It was found that widdrol induces accumulation of sub-G1 phase and arrests in the G1 phase of the cell cycle. Induction of G1 arrest by widdrol was correlated with induction of Chk2, p53 phosphorylation and CDK inhibitor p21 expression as well as inhibition of cyclin E, cyclin-dependent kinase (CDK2) and retinoblastoma protein (pRB). Moreover, mini-chromosome maintenance (MCM) proteins were markedly down-regulated in HT29 cells treated with widdrol. Altogether, these results show widdrol possesses potential anti-cancer activity against colon adenocarcinoma cells by inhibiting their proliferation and inducing cell cycle G1 arrest. 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828235     DOI: 10.1016/j.canlet.2009.09.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Widdrol activates DNA damage checkpoint through the signaling Chk2-p53-Cdc25A-p21-MCM4 pathway in HT29 cells.

Authors:  Hee Jung Yun; Sook Kyung Hyun; Jung Ha Park; Byung Woo Kim; Hyun Ju Kwon
Journal:  Mol Cell Biochem       Date:  2011-12-11       Impact factor: 3.396

2.  Widdrol-induced lipolysis is mediated by PKC and MEK/ERK in 3T3-L1 adipocytes.

Authors:  Hyun Young Jeong; Hee Jung Yun; Byung Woo Kim; Eun Woo Lee; Hyun Ju Kwon
Journal:  Mol Cell Biochem       Date:  2015-09-10       Impact factor: 3.396

3.  MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.

Authors:  Wei-Ming Li; Chun-Nung Huang; Hung-Lung Ke; Ching-Chia Li; Yu-Ching Wei; Hsin-Chih Yeh; Lin-Li Chang; Chun-Hsiung Huang; Peir-In Liang; Bi-Wen Yeh; Ti-Chun Chan; Chien-Feng Li; Wen-Jeng Wu
Journal:  Oncotarget       Date:  2016-11-22

Review 4.  The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.

Authors:  Yeon-Soo Seo; Young-Hoon Kang
Journal:  Front Mol Biosci       Date:  2018-03-29

5.  Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells.

Authors:  Blanca L Valle; Theresa D'Souza; Kevin G Becker; William H Wood; Yongqing Zhang; Robert P Wersto; Patrice J Morin
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

Review 6.  The Mcm2-7 replicative helicase: a promising chemotherapeutic target.

Authors:  Nicholas E Simon; Anthony Schwacha
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

7.  Daucus carota pentane-based fractions arrest the cell cycle and increase apoptosis in MDA-MB-231 breast cancer cells.

Authors:  Wassim N Shebaby; Mohammad Mroueh; Kikki Bodman-Smith; Anthony Mansour; Robin I Taleb; Costantine F Daher; Mirvat El-Sibai
Journal:  BMC Complement Altern Med       Date:  2014-10-10       Impact factor: 3.659

8.  Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract.

Authors:  Zong-Keng Kuo; Mei-Wei Lin; I-Huang Lu; Hsin-Jan Yao; Hsin-Chieh Wu; Chun-Chung Wang; Shyh-Horng Lin; Si-Yuan Wu; Tien-Soung Tong; Yi-Cheng Cheng; Jui-Hung Yen; Ching-Huai Ko; Shu-Jiau Chiou; I-Horng Pan; Hsiang-Wen Tseng
Journal:  BMC Complement Altern Med       Date:  2016-08-08       Impact factor: 3.659

Review 9.  Post-Translational Modifications of the Mini-Chromosome Maintenance Proteins in DNA Replication.

Authors:  Zheng Li; Xingzhi Xu
Journal:  Genes (Basel)       Date:  2019-04-30       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.